ERBB2 and breast carcinoma: PD-L1 expression was preferentially detected in HER2+ breast tumors showing a strong cytotoxic local immune response (162) and the numbers of PD-1+ tumor-infiltrating lymphocytes were associated with poor prognosis in HER2+ breast cancer (163, 164).